Hydrogel nanoparticles as new drug delivery system for CNS disorders

Abstract Previous studies have shown that more than one million individuals suffer from central nervous system (CNS) diseases worldwide. Nanogels are a good way to deliver drugs because they are ultra‐stable, can hold a lot of drugs, have a core‐shell structure, are very permeable, and can get into brain tissue both in the lab and in living organisms. The blood‐brain barrier (BBB) and the blood‐cerebrospinal fluid barrier (BCSFB) make it harder to deliver therapies to specific areas of the CNS because drugs can′t get into the brain well enough. However, these barriers help treat neurological disorders like epilepsy, neurodegenerative diseases, brain tumors, and ischemic stroke. A number of biological studies suggest that nano‐additives may improve the shape, mechanical properties, electrical conductivity, and biological activities of hydrogels. The creation of nanogels for CNS drug delivery, their early preclinical success, and their potential for neurotoxicity are all examined in this research. This study looks at techniques that are almost ready for clinical use, a preclinical delivery system for the CNS, and the use of nanogels as a successful BBB‐penetration method. It also examines the main difficulties that nanogels must overcome in order to provide the most effective therapeutic care for CNS illnesses.